BRCA2 and neoplasm: Tumours generated from the triple deletion (Trp53-/-;Brca2-/-;Pten-/-) had significantly shorter survival (40 days) than Trp53-/- and Trp53-/-;Brca2-/- tumours (57 days), but longer survival than Trp53-/-;Pten-/-.